REFERENCES
- Albertazzi P., Purdie D. W. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas 2002; 42: 173–185, [INFOTRIEVE], [CSA]
- Anderson J. M., Johnstone B. M., Cook-Newell M. E. Meta-analysis of soy protein intake on serum lipids. N. Engl. J. Med. 1995; 333: 276–282, [INFOTRIEVE], [CSA], [CROSSREF]
- Arjmandi B. H., Alekel L., Hollis B. W., et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J. Nutr. 1996; 126: 161–167, [INFOTRIEVE], [CSA]
- Arjmandi B. H., Smith B. J. Soy isoflavones' osteoprotective role in postmenopausal women: mechanism of action. J. Nutr. Biochem. 2002; 13: 130–137, [INFOTRIEVE], [CSA], [CROSSREF]
- Bloedon L., Jeffcoat A. R., Lopaczynski W., et al. Safety and pharmacokinetics of purified soy isoflavones: single dose administration to postmenopausal women. Am. J. Clin. Nutr. 2002; 76: 1126–1137, [INFOTRIEVE], [CSA]
- Bovee T. F. H., Helsdinger R. J. R., Rietjens I. M. C. M., et al. Rapid yeast bioassays stably expressing human estrogen receptors α and β, and green fluorescent protein: a comparison of different compounds with both receptor types. J. Steroid Biochem. Mol. Biol. 2004; 91: 99–109, [INFOTRIEVE], [CSA], [CROSSREF]
- Faughnan M. S., Hawdon A., Ah-Singh E., et al. Urinary isoflavone kinetics: the effect of age, gender, food matrix and chemical composition. Br. J. Nutr. 2004; 91: 567–574, [INFOTRIEVE], [CSA], [CROSSREF]
- Fritz W. A., Coward L., Wang J., Lamamrtiniere C. A. Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenenesis 1998; 19: 2151–2158, [CSA], [CROSSREF]
- Gaillard P., Carrupt P. A., Testa B., Boudon A. Molecular lipophilicity potential in 3D-QSAR: method and applications. J. Comput. Aided Mol. Design 1994; 8: 83–96, [CSA], [CROSSREF]
- Glazier M. G., Bowman M. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch. Intern. Med. 2001; 161: 1161–1172, [INFOTRIEVE], [CSA], [CROSSREF]
- Jacobsen B. K., Knutsen S. F., Fraer G. E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998; 9: 553–557, [INFOTRIEVE], [CSA], [CROSSREF]
- Kreijkamp-Kasper S., Kok L., Grobbee D. E., et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004; 292: 65–74, [CSA], [CROSSREF]
- Kuiper G., Carlsson B., Grandien K., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors and α and β. Endocrinology 1997; 138: 863–870, [INFOTRIEVE], [CSA], [CROSSREF]
- Lee H. P., Gourley L., Duffy S. W., et al. Dietary effects on breast-cancer risk in Singapore. Lancet 1991; 337: 1197–1200, [INFOTRIEVE], [CSA], [CROSSREF]
- Minghetti P., Casiraghi A., Cilurzo F., et al. Comparison of different membranes with cultures of keratinocytes from man for percutaneous absorption of nitroglycerin. J. Pharm. Pharmacol. 1999a; 51: 729–734, [CSA], [CROSSREF]
- Minghetti P., Casiraghi A., Montanari L., Monzani M. V. In vitro skin permeation of Sinitrodil, a member of a new class of nitrovasodilator drugs. Eur. J. Pharm. Sci. 1999b; 7: 231–236, [INFOTRIEVE], [CSA], [CROSSREF]
- Minghetti P., Cilurzo F., Casiraghi A., et al. Development of patches for the controlled release of dehydroepiandrosterone. Drug Dev. Ind. Pharm. 2001; 27: 113–119, [CSA], [CROSSREF]
- Pedretti A., Villa L., Vistoli G. VEGA: A versatile program to convert, handle and visualize molecular structure on windows-based PCs. J. Mol. Graph. 2002; 21: 47–49, [CSA], [CROSSREF]
- Scarabin P., Alhenc-Gelas M., Plu-Bureau G., et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 1997; 17: e3071–e3078, [CSA]
- Setchell K., Brown N. M., Desai P., et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavones supplements. J. Nutr. 2001; 131: 1362S–1375S, [INFOTRIEVE], [CSA]
- Setchell K., Brown N. M., Desai P., et al. Bioavailability disposition and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J. Nutr. 2003a; 133: 1027–1035, [INFOTRIEVE], [CSA]
- Setchell K., Faughnan M. S., Avades T., et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracer in premenopaual women. Am. J. Clin. Nutr. 2003b; 77: 411–419, [INFOTRIEVE], [CSA]
- Squadrito F., Altavilla D., Crisafulli A., et al. Effect of genistein on endothelial function in postmenopausal women: a randomized, double blind, controlled study. Am. J. Med. 2003; 144: 470–476, [CSA], [CROSSREF]
- Vanttnen K., Moravcova J. Transdermal absorption of phytoestrogens. Pharmazie 2001; 56: 711–717, [CSA]
- Zhang Y., Wang G. J., Song T., et al. Urinary disposition of the soybean isoflavones daidzein, genistein and glycitein differ among humans with moderate fecal isoflavone degradation activity. J. Nutr. 1999; 129: 957–962, [INFOTRIEVE], [CSA]
- Zubik L., Meydani M. Bioavailability of soybean isoflavones from aglycone and glucoside forms in American women. Am. J. Clin. Nutr. 2003; 77: 1459–1465, [INFOTRIEVE], [CSA]